Contact this trialFirst, we need to learn more about you.
Epigenetic Modifying Agent
BGB-11417 for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Recruiting1 awardPhase 1 & 2
Milwaukee, Wisconsin
This trial tests a new drug, BGB-11417, alone and with azacitidine, in patients with certain blood cancers to see if it is safe and effective, and to find the best dose.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service